William F. Hahne
Corporate Officer/Principal bei BIO-PATH HOLDINGS, INC.
Aktive Positionen von William F. Hahne
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| BIO-PATH HOLDINGS, INC. | Corporate Officer/Principal | - | - |
| Technik-/Wissenschafts-/F&E-Leiter | 17.04.2017 | - |
Karriereverlauf von William F. Hahne
Ehemalige bekannte Positionen von William F. Hahne
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| IMUNON, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2006 | 01.12.2007 |
CuraGen Corp.
 CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2003 | 01.01.2005 |
Eisai, Inc.
 Eisai, Inc. Pharmaceuticals: MajorHealth Technology Eisai, Inc. manufactures pharmaceuticals products. It focuses on neurology, gastrointestinal disorders and oncology critical care. The company was founded in 1995 and is headquartered in Woodcliff Lake, NJ. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.1997 | 01.01.2002 |
Vion Pharmaceuticals, Inc.
 Vion Pharmaceuticals, Inc. BiotechnologyHealth Technology Vion Pharmaceuticals, Inc. develops therapeutics for the treatment of cancer. The company was founded in March 1992 and is headquartered in New Haven, CT. | Technik-/Wissenschafts-/F&E-Leiter | 01.02.2008 | - |
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
Ausbildung von William F. Hahne
| Cornell University | Doctorate Degree |
| Grinnell College | Undergraduate Degree |
Statistik
International
| Vereinigte Staaten | 8 |
Operativ
| Chief Tech/Sci/R&D Officer | 6 |
| Doctorate Degree | 1 |
| Corporate Officer/Principal | 1 |
Sektoral
| Health Technology | 6 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| IMUNON, INC. | Health Technology |
| BIO-PATH HOLDINGS, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Health Technology |
Vion Pharmaceuticals, Inc.
Vion Pharmaceuticals, Inc. BiotechnologyHealth Technology Vion Pharmaceuticals, Inc. develops therapeutics for the treatment of cancer. The company was founded in March 1992 and is headquartered in New Haven, CT. | Health Technology |
Eisai, Inc.
Eisai, Inc. Pharmaceuticals: MajorHealth Technology Eisai, Inc. manufactures pharmaceuticals products. It focuses on neurology, gastrointestinal disorders and oncology critical care. The company was founded in 1995 and is headquartered in Woodcliff Lake, NJ. | Health Technology |
- Börse
- Insiders
- William F. Hahne
- Erfahrung
